Abivax Shares Break Resistance at €115 and Gain Nearly 13% in One Week
The French biotech regains control during the session after several days of volatility below €118. The stock has crossed a closely monitored technical threshold since last week's quarterly publication, ranking among the top gainers in the SBF 120 at midday.
A Technical Breakthrough Above €115.10 Unlocks the Configuration
Abivax shares are up 3.29% at €116.10 at midday, while the SBF 120 is down 0.26%. The stock has broken its resistance at €115.10 during the session and remains above it, unlocking a configuration previously capped below €118. The price is now significantly above its three moving averages, with a gap of 11.73% over the MM20 (€103.91) and 24.36% over the MM200 (€93.36). The RSI at 60 remains in a neutral zone, which leaves room before an overbought signal, while the weekly performance is close to 13%. The session continues a momentum that saw the stock cross a financial milestone at the beginning of May, with the repurchase of royalty certificates and the raising of $45 million.
Strong Clinical Data but Faster Cash Burn
The biotech released its first quarter 2026 accounts on May 22. Obevazimod, its candidate for ulcerative colitis, shows 68% of patients in clinical remission at three years on a reduced dose, with no new safety signals over seven years. However, the operational loss widened to €56.2 million from €47.2 million a year earlier, driven by an additional €10.2 million in R&D expenses. During this publication, the company confirmed financial visibility until the fourth quarter of 2027, backed by €491.6 million in cash, and the planned launch at the end of the second quarter of 2026 of the phase 3 maintenance trial ABTECT. According to reviewed statements, three funds cumulatively hold 2.94% of the capital sold short, a very slight increase (+0.13 point in one month). The level remains contained and the thirty-day dynamic does not indicate a marked increase in bearish bets, although some institutional investors maintain a bearish stance on the stock. The maintenance above the €115.10 threshold will be a key observable element in the upcoming sessions, in anticipation of the start of the ABTECT trial.
